Alimta 100 mg (Pemetrexed (Pemetrexed Disodium) POWDER FOR SOLUTION) 100 MG

Alimta 100 mg is a powder for solution used in intravenous therapy. This medication, containing pemetrexed disodium, is commonly prescribed for certain types of cancer treatments. Learn more about its uses and effects.

Strength

100 MG

Pack Size

4.2ML

Manufacturer / TM Owner

ELI LILLY CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Alimta 100 mg is primarily used in the treatment of specific types of cancer. Pemetrexed disodium, the active ingredient, is often utilized in combination with other therapies to target cancer cells. Patients may wonder, 'What is Alimta used for?' This medication is typically administered intravenously and is part of a broader cancer treatment plan.

Side Effects

Common effects of Alimta 100 mg may include fatigue, nausea, and vomiting. Some patients might experience a decrease in blood cell counts, which can lead to increased susceptibility to infections. It's important to discuss any unusual symptoms with a healthcare provider.

Precautions & Warnings

Alimta 100 mg should be handled with care, as it is a potent medication. It is essential to follow the prescribed dosage and administration guidelines provided by a healthcare professional. Patients should inform their doctor about any existing medical conditions or allergies before starting treatment.

Avoid Interactions

Alimta 100 mg may interact with certain medications, including those that affect the immune system or blood cell production. It is crucial to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other substances may also affect the efficacy and safety of this medication.

Frequently Asked Questions

Alimta 100 mg is used in the treatment of specific types of cancer, often in combination with other therapies.

Alimta 100 mg is administered intravenously as a powder for solution.

Common side effects may include fatigue, nausea, vomiting, and a decrease in blood cell counts.

It is important to consult a healthcare provider before taking Alimta 100 mg with other medications to avoid potential interactions.

Patients should follow prescribed dosage guidelines and inform their doctor about any existing medical conditions or allergies.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.